MTOR and diabetic kidney disease: In addition, sodium-glucose contransporter-2 (SGLT2) inhibitors exert their effects on oxidative stress and inflammation, while glucagon-like peptide 1 (GLP-1) receptor agonists act on the AMPK-mammalian target of rapamycin (mTOR)-autophagy-ROS-signaling axis, and both were shown to be effective in animal models of DKD [17,18].